Literature DB >> 10605016

IFN-gamma-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells.

J K Lee1, T J Sayers, A D Brooks, T C Back, H A Young, K L Komschlies, J M Wigginton, R H Wiltrout.   

Abstract

The role of Fas in the regulation of solid tumor growth was investigated. Murine renal carcinoma (Renca) cells were constitutively resistant to Fas-mediated killing in vitro, but exhibited increased expression of Fas and sensitivity to Fas-mediated killing after exposure to IFN-gamma and TNF. Transfected Renca cells overexpressing Fas were efficiently killed in vitro upon exposure to anti-Fas Ab (Jo2). When Fas-overexpressing Renca cells were injected into syngenic BALB/c mice, there was a consistent and significant delay in tumor progression, reduced metastasis, and prolonged survival that was not observed for Renca cells that overexpressed a truncated nonfunctional Fas receptor. The delay of in vivo tumor growth induced by Fas overexpression was not observed in IFN-gamma-/- mice, indicating that IFN-gamma is required for the delay of in vivo tumor growth. However, there was a significant increase of infiltrated T cells and in vivo apoptosis in Fas-overexpressing Renca tumors, and Fas-overexpressing Renca cells were also efficiently killed in vitro by T cells. In addition, a strong therapeutic effect was observed on Fas-overexpressing tumor cells by in vivo administration of anti-Fas Ab, confirming that overexpressed Fas provides a functional target in vivo for Fas-specific ligands. Therefore, our findings demonstrate that Fas overexpression on solid tumor cells can delay tumor growth and provides a rationale for therapeutic manipulation of Fas expression as a means of inducing tumor regression in vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10605016     DOI: 10.4049/jimmunol.164.1.231

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

Review 1.  IFN-γ: A cytokine at the right time, is in the right place.

Authors:  J Daniel Burke; Howard A Young
Journal:  Semin Immunol       Date:  2019-06-17       Impact factor: 11.130

2.  IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy.

Authors:  J M Wigginton; E Gruys; L Geiselhart; J Subleski; K L Komschlies; J W Park; T A Wiltrout; K Nagashima; T C Back; R H Wiltrout
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

3.  Anti-idiotype antibody induced cellular immunity in mice transgenic for human carcinoembryonic antigen.

Authors:  Asim Saha; Sunil K Chatterjee; Kenneth A Foon; Malaya Bhattacharya-Chatterjee
Journal:  Immunology       Date:  2006-08       Impact factor: 7.397

4.  Coactivation of AKT and β-catenin in mice rapidly induces formation of lipogenic liver tumors.

Authors:  Jimmy K Stauffer; Anthony J Scarzello; Jesper B Andersen; Rachel L De Kluyver; Timothy C Back; Jonathan M Weiss; Snorri S Thorgeirsson; Robert H Wiltrout
Journal:  Cancer Res       Date:  2011-02-15       Impact factor: 12.701

Review 5.  Intravital imaging of CD8+ T cell function in cancer.

Authors:  Thorsten R Mempel; Christian A Bauer
Journal:  Clin Exp Metastasis       Date:  2008-07-30       Impact factor: 5.150

6.  Essential role for hematopoietic Fas ligand (FasL) in the suppression of melanoma lung metastasis revealed in bone marrow chimeric mice.

Authors:  Christopher L Hall; Mike Yao; Laurie L Hill; Laurie B Owen-Schaub
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

7.  Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity.

Authors:  Anil Shanker; Samuel T Pellom; Duafalia F Dudimah; Menaka C Thounaojam; Rachel L de Kluyver; Alan D Brooks; Hideo Yagita; Daniel W McVicar; William J Murphy; Dan L Longo; Thomas J Sayers
Journal:  Cancer Res       Date:  2015-10-22       Impact factor: 12.701

8.  Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity.

Authors:  Anil Shanker; Alan D Brooks; Kristen M Jacobsen; John W Wine; Robert H Wiltrout; Hideo Yagita; Thomas J Sayers
Journal:  Cancer Res       Date:  2009-08-04       Impact factor: 12.701

9.  Association between a high-expressing interferon-gamma allele and a lower frequency of kidney angiomyolipomas in TSC2 patients.

Authors:  Sandra L Dabora; Penelope Roberts; Andres Nieto; Ron Perez; Sergiusz Jozwiak; David Franz; John Bissler; Elizabeth A Thiele; Katherine Sims; David J Kwiatkowski
Journal:  Am J Hum Genet       Date:  2002-08-21       Impact factor: 11.025

10.  Genetics and molecular biology of tuberous sclerosis complex.

Authors:  Valerio Napolioni; Paolo Curatolo
Journal:  Curr Genomics       Date:  2008-11       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.